- ISIN
- US14167L1035
- CUSIP
- 14167L103
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- IPO Date
- Jul 17, 2014
Highlights
- Market Cap
- $2.26B
- Enterprise Value
- $1.90B
- EPS (TTM)
- $2.10
- PE Ratio
- 20.81
- PEG Ratio
- 0.03
- Total Revenue (TTM)
- $458.09M
- Gross Profit (TTM)
- $225.02M
- EBITDA (TTM)
- $129.64M
- Year Range
- $11.26 - $45.00
- Target Price
- $40.00
- ROA (TTM)
- 20.83%
- ROE (TTM)
- 26.08%
- Avg. Volume (1M)
- 1M
- Avg. Volume Value (1M)
- $43.11M
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
CDNA Performance Chart
CareDx, Inc (CDNA) is up 132.0% since the beginning of the year. At $44 per share, CDNA is trading just below its 52-week high of $45. Investors who bought $1,000 worth of CDNA shares 5 years ago would now be looking at an investment worth $520.
Loading charts...
Compare this symbol against anything
Returns By Period
CareDx, Inc (CDNA) has returned 132.01% so far this year and 257.69% over the past 12 months. Looking at the last ten years, CDNA has achieved an annualized return of 25.04%, outperforming the S&P 500 Index benchmark, which averaged 13.26% per year.
CareDx, Inc
- 1D
- 14.72%
- 1M
- 49.74%
- 6M
- 112.70%
- YTD
- 132.01%
- 1Y
- 257.69%
- 3Y*
- 60.92%
- 5Y*
- -12.26%
- 10Y*
- 25.04%
- ALL TIME*
- 13.52%
Benchmark (S&P 500 Index)
- 1D
- 0.70%
- 1M
- 0.09%
- 6M
- 7.94%
- YTD
- 9.41%
- 1Y
- 20.07%
- 3Y*
- 17.84%
- 5Y*
- 11.25%
- 10Y*
- 13.26%
- ALL TIME*
- 8.09%
CDNA Monthly Returns History
Based on dividend-adjusted daily data since Jul 17, 2014, CDNA's average daily return is +0.17%, while the average monthly return is +3.55%. At this rate, an investment would double in approximately 1.7 years.
Historically, 54% of months were positive and 46% were negative. The best month was Aug 2017 with a return of +115.0%, while the worst month was Mar 2023 at -45.7%. The longest winning streak lasted 8 consecutive months, and the longest losing streak was 6 months.
On a daily basis, CDNA closed higher 49% of trading days. The best single day was May 4, 2017 with a return of +35.6%, while the worst single day was Sep 28, 2015 at -40.9%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 9.08% | -8.71% | -7.46% | 19.87% | 9.66% | 24.89% | 53.37% | 132.01% | |||||
| 2025 | 8.83% | -4.94% | -19.86% | -4.90% | 0.65% | 15.01% | -37.13% | 11.19% | 6.44% | 3.16% | 19.13% | 5.43% | -12.00% |
| 2024 | -28.67% | 24.30% | -0.47% | -26.72% | 67.65% | 19.37% | 28.72% | 53.73% | 1.61% | -29.13% | 10.89% | -12.75% | 78.42% |
| 2023 | 30.94% | 12.58% | -45.66% | -11.49% | -1.36% | 6.52% | 28.35% | -14.67% | -24.81% | -22.71% | 79.48% | 23.58% | 5.17% |
| 2022 | -8.09% | -8.18% | -3.62% | -17.71% | -17.38% | -14.59% | 10.75% | -17.65% | -13.12% | 16.98% | -34.96% | -11.89% | -74.91% |
| 2021 | 5.49% | 3.47% | -13.90% | 16.13% | 1.68% | 13.83% | -8.17% | -12.80% | -13.52% | -19.52% | -15.41% | 5.42% | -37.23% |
Benchmark Metrics
CareDx, Inc has an annualized alpha of 28.88%, beta of 1.34, and R2 of 0.09 versus S&P 500 Index. Calculated based on daily prices since July 17, 2014.
- This stock captured 194.50% of S&P 500 Index gains and 169.04% of its losses - amplifying both gains and losses, but participating more in upside than downside.
- R2 of 0.09 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 28.88%
- Beta
- 1.34
- R²
- 0.09
- Upside Capture
- 194.50%
- Downside Capture
- 169.04%
Return for Risk
Risk / Return Rank
CDNA ranks 98 for risk / return — above 98% of stocks peers on PortfoliosLab. Its historical combined result is among the stronger results in the peer group.
Risk / Return Metrics
The table below present risk-adjusted performance metrics for CareDx, Inc (CDNA) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| CDNA | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +2.17 | ||
| Sortino ratioReturn per unit of downside risk | +2.62 | ||
| Omega ratioGain probability vs. loss probability | 1.54 | 1.25 | +0.28 |
| Calmar ratioReturn relative to maximum drawdown | 10.90 | 2.00 | +8.89 |
| Martin ratioReturn relative to average drawdown | 32.58 | 8.49 | +24.09 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the CareDx, Inc. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the CareDx, Inc was 94.87%, occurring on Oct 25, 2023. The portfolio has not yet recovered.
The current CareDx, Inc drawdown is 54.28%.
Drawdown | Fall | Recovery | Underwater | Related event |
|---|---|---|---|---|
-94.87%Oct 2023 | 2y 9mo | — | 5y 6moJan 2021 - now | — |
-92.75%Apr 2017 | 2y 7mo | 1y 12d | 3y 8moSep 2014 - May 2018 | — |
-65.22%Mar 2020 | 8mo 10d | 6mo 17d | 1y 2moJul 2019 - Oct 2020 | COVID crash2020 |
-34.25%Apr 2019 | 1mo 1d | 1mo 28d | 2mo 29dMar 2019 - Jun 2019 | — |
-33.74%Dec 2018 | 17d | 2mo 8d | 2mo 25dDec 2018 - Feb 2019 | Rate-hike selloffLate 2018 |
Drawdown Indicators
| CDNA | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -94.87% | -56.78% | -38.09% |
Max Drawdown (1Y)Largest decline over 1 year | -23.64% | -9.10% | -14.54% |
Max Drawdown (3Y)Largest decline over 3 years | -65.96% | -18.90% | -47.06% |
Max Drawdown (5Y)Largest decline over 5 years | -94.19% | -25.43% | -68.76% |
Max Drawdown (10Y)Largest decline over 10 years | -94.87% | -33.92% | -60.95% |
Current DrawdownCurrent decline from peak | -54.28% | -1.58% | -52.70% |
Average DrawdownAverage peak-to-trough decline | -53.87% | -10.70% | -43.17% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 7.89% | 2.14% | +5.75% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of CareDx, Inc over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how CareDx, Inc is priced in the market compared to other companies in the Diagnostics & Research industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PE Ratio
The chart displays the Price-to-Earnings (P/E) ratio for CDNA, comparing it with other companies in the Diagnostics & Research industry. Currently, CDNA has a P/E ratio of 20.8. This P/E ratio is considered low compared to industry peers, which may suggest that the stock is undervalued or that the company has weaker growth prospects.
PEG Ratio
The chart shows the Price/Earnings to Growth (PEG) ratio for CDNA compared to other companies in the Diagnostics & Research industry. CDNA currently has a PEG ratio of 0.0. This PEG ratio is low compared to industry peers, which could indicate the stock is undervalued relative to its expected growth.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for CDNA relative to other companies in the Diagnostics & Research industry. Currently, CDNA has a P/S ratio of 5.0. This P/S ratio falls within the average range for the industry, suggesting the stock is fairly valued based on its revenue.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for CDNA in comparison with other companies in the Diagnostics & Research industry. Currently, CDNA has a P/B value of 5.5. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.
Income Statement
| TTM | |
|---|---|
Revenue | |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with CDNA
Add CareDx, Inc to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with CDNA